35 Percent Crash Warning and Seven Stocks: Which Is the Best Buy?

Everything opens with a frightening headline: a bearish scenario calling for a 35 percent market fall by the end of 2027. The host immediately applies the brakes, stressing this is one institution's bear case and no evidence that a crash has already begun. Context comes from Fitch-flavored warnings, where an AI bubble unwind could bring a sharp drawdown and recession risk. I read this picture against the Fitch warning and verified the details through the moneycontrol.com source, which documents the recession angle thoroughly for cautious readers today.

Market backdrop: yields, oil and the Fed

The reasons behind the tension are built with numbers: elevated bond yields and expensive oil make a broad rally harder. When yields rise, equities face tougher competition and debt-funded companies clear a higher hurdle. The latest jobs report softened Fed expectations, with the Tom Lee camp arguing cooling inflation will relieve rates. The counterargument is crisp: with growth intact, rates stay high and compress S and P multiples. Evidence that low-debt sectors held up better in the third quarter feeds into the analysis.

Method: weakest opportunity to strongest

The ranking rule is simple and declared upfront: seven steps from the weakest buying opportunity to the strongest. Each company passes through three lenses: forward multiples , a dividend model and discounted cash flow . The gap between the resulting blended value and the market price is read as the margin of safety . But the host warns against deceptive averages; when two methods disagree wildly, he refuses the average and interrogates which assumption is fragile. That discipline keeps the whole list readable.

Lower rungs: discount with baggage

Seventh place goes to NextEra, and the story looks tempting at first: a forward earnings multiple of 18.4 against a five-year average of 22.8, plus a 3.2 percent dividend yield above its history. Near double-digit revenue growth expectations and a price below the bottom of the fair-value band add spice. Yet the balance sheet is heavy, with net debt to EBITDA near seven times and the forecast decline still undelivered. Giant grid investments drain the coffers while regulatory approvals take time. Blended value lands at 94 dollars versus a Street average near 100, but the multiple method says 72 and the dividend model says 117. I examined the Fitch rating affirmation notes and the Dominion watch commentary through the investor.nexteraenergy.com source and added that institutional perspective to the table carefully.

Sixth place belongs to AbbVie, the mirror image of NextEra: the business performs and the price largely reflects it. The shares trade near 262 dollars, up 15 percent year to date, with gross margins of 73 percent and operating margins of 36 percent backing quality. Growth expectations run at 9 to 10 percent for sales and around 17 percent for earnings. But the forward multiple of 17.3 sits above its five-year 14.4 average while the yield trails history. Excitement over the new Parkinson therapy is genuine, as the US Food and Drug Administration approved the tavapadon-based medicine in late September and I confirmed that decision through the news.abbvie.com source for accuracy. Still, the sales contribution is uncertain and the 293 dollar model value leaves only an 11 percent cushion.

Fifth place is Microsoft, the most instructive stop on the list: a superb company with a mediocre buying setup. The stock sits near 517 dollars, close to its highs, while growth expectations stay strong at 18 to 19 percent for revenue and 20 percent for earnings. A multiple of 26 against a five-year 30 average means no historic premium is demanded. The problem is cash: operating cash flow rose 34 percent while free cash flow collapsed, because massive investment absorbs whatever remains. The conservative model values it at 527 dollars with a mere 2 percent cushion. I checked the long-term free cash flow history through the macrotrends.net source and saw clearly how the investment pace explains this picture today.

Mid-table: strong growth, expensive proof

Fourth place goes to Meta, transformed by a 23 percent rally over the last month. The shares trade near 728 dollars, close to highs, with revenue growth expectations of 23 percent, the strongest on the list, and earnings compounding near 20 percent. The AI-powered discovery and advertising idea is commercially powerful, yet the 2030 scenarios swing between 2.4 and 36 billion dollars. A forward price-earnings ratio of 23 runs slightly above history. While free cash flow falls by double digits, the model assumes a leap from 2 billion in 2026 to 95 billion in 2030. I followed the coverage of AI agents reaching into travel bookings through the cnn.com source and added this competitive dimension to my notes. Value lands at 832 dollars with a 13 percent cushion, all conditional on cash recovery.

Third place is Amazon, presented as the case where an optically cheap multiple must be read carefully. The stock sits near 250 dollars, mid-range of its 52-week band, while the Street average at 330 dollars implies over 30 percent upside. Cloud carries the investment thesis and advertising revenues approached 69 billion dollars in 2025. Trailing operating cash flow of 161 billion dollars proves firepower, but that figure precedes investment; the real question is what remains afterward. Net debt near 0.6 times gives comfort, yet the model assumes 175 billion dollars of free cash in 2030. I verified the cloud acceleration in the second-quarter results through the ir.aboutamazon.com source and approached the calculation within that confirmed framework. Value comes to 348 dollars with a 28 percent cushion, a patient investor share.

Top: price backed by present earnings

Second place goes to American Express with a crisp thesis: falling price, healthy franchise, testable profitability. The shares trade near 300 dollars, down 18 percent year to date, with a forward multiple of 16.3 below the five-year 17.7 average. Average quarterly fees per card rose from 61 to 131 dollars, showing strengthening customer economics. Revenue growth near 10 percent and earnings near 13 percent are expected, with a blended value of 386 dollars and a 22 percent cushion. The caveat matters: customer and rewards expenses outgrew revenue while profit guidance stayed flat. I read the July report on raised guidance powered by affluent spending through the reuters.com source and worked it into the table. As a lender, the earnings multiple deserves more weight than a free cash flow model.

First place goes to Booking with the widest cushion on the board: the 265 dollar model dwarfs the market price, implying 40 percent. The shares are down 26 percent year to date, with a forward price-earnings ratio of 14.2 far below the historical 20.4 average. Shares outstanding shrank 39 percent since 2016, and free cash flow per share reached about 11 dollars in 2025. Revenue growth of 10 to 11 percent and earnings growth of 18 percent are expected, while the model assumes only 4 percent cash growth, hence modest. The risk has a name: after the Meta AI agent and Expedia partnership, travel shares sold off hard in September. I tracked the scale of that selloff through the 247wallst.com source and added it to the risk premium in this ranking. Should the threat turn into lasting damage, the model breaks.

Summing up, the picture reads as follows: seventh NextEra between discount and debt load, sixth AbbVie between quality and premium price, fifth Microsoft between a wonderful business and a thin cushion, fourth Meta between powerful growth and a giant cash assumption, third Amazon between cloud strength and the investment bill, second American Express between a falling multiple and rising customer costs, and first Booking between a wide cushion and the AI threat. At every step the question repeats: which adverse scenario can the price still survive?

The crash warning deserves the same lens. The 35 percent scenario points to the end of 2027 and represents a single bearish view, useful not for timing but for stress-testing assumptions. If rates stay high, multiples compress; if growth persists, earnings hold; both can happen together. Hence the host advice is clear: stop predicting the whole market and hunt for a sensible price, credible assumptions and room for error. The note that technology proved relatively resilient over three months while levered balance sheets looked fragile fits this frame.

On the practical side, the signals to watch are well defined. At NextEra, whether leverage truly falls toward 5.3 times; at AbbVie, how fast the new drug converts into sales; at Microsoft and Meta, the return to cash after investment; at Amazon, the translation of cloud and advertising into free cash; at American Express, credit losses and reward costs; at Booking, whether AI agents touch commissions. Should any of these break, the corresponding margin of safety erodes fast. Purchase decisions belong on that calendar.

The final word: the list earns its keep by breaking the good company equals good purchase reflex. Loving the business while disliking the price is possible at Microsoft and Meta, just as liking the price while pricing the risk is possible at Booking and American Express. My reading leans the same way, since the two names that pay with present earnings sleep better than the five carrying assumption loads. Yet if the AI threat is underestimated, the crown changes hands quickly. Writing down which assumption you dispute makes the list stronger.